

## List of Tables

Table 2.1: Classification of a TB Case.....	2-4
Table 2.2: Respiratory vs. Non-respiratory TB Disease.....	2-11
Table 2.3: Risk Factors for the Development of Active TB Among People with a Positive Tuberculin Skin Test (Presumed Infected With <i>Mycobacterium Tuberculosis</i> ).....	2-12
Table 2.4: Other Factors for Disease Development.....	2-13
Table 3.1: Adverse Events Following BCG Vaccine and Suggested Management.....	3-8
Table 3.2: BCG Vaccine Usage in Canada.....	3-9
Table 4.1: Tuberculin Skin Test Cut-points for Interpretation of the TST.....	4-10
Table 4.2: QuantiFERON®-TB Gold (QFT) Assay.....	4-17
Table 4.3: Advantages and Disadvantages of IGRA Tests.....	4-18
Table 6.1: Latent TB Infection Versus Active Respiratory TB Disease.....	6-2
Table 6.2: Symptoms of Pulmonary TB Disease.....	6-6
Table 6.3: Infectivity Continuum.....	6-9
Table 6.4: Number of Bacteria Seen on Microscopy and Laboratory Interpretation.....	6-10
Table 6.5: Symptoms of Non-respiratory TB for Selected Sites.....	6-17
Table 7.1: Risk Assessment – Admission to Health Care Facility.....	7-9
Table 7.2: Recommended Air Exchanges per Area (Health Care Facilities).....	7-11
Table 7.3: Time Needed (by Number of Air Changes per Hour) to Remove Airborne Microorganisms After Generation of Infectious Droplet Nuclei has Ceased.....	7-12
Table 8.1: Regimes for Treatment of Latent TB Infection.....	8-5
Table 8.2: INH Protocol for Treatment of LTBI.....	8-5
Table 8.3: Special Considerations in the Treatment of LTBI.....	8-6
Table 8.4: Summary of Care for Patients Receiving Treatment for LTBI.....	8-8
Table 8.5: Symptoms of Toxicity.....	8-9
Table 8.6: INH Drug Overdose.....	8-11
Table 8.7: Management of Treatment Interruptions.....	8-17
Table 8.8: Special Considerations in the Treatment of Active TB Disease.....	8-18
Table 8.9: Recommended Drug Regime.....	8-21
Table 8.10: Recommended Drug Doses for Daily and Intermittent Therapy in Adolescents and Adults.....	8-22

Table 8.11: Summary of Care for Patients Receiving Treatment for Active TB.....	8-24
Table 8.12: Common Adverse Reactions with First Line Anti-Tuberculosis Drugs.....	8-25
Table 8.13: INH Drug Overdose.....	8-29
Table 8.14: Type of Drug Resistance.....	8-31
Table 8.15: Regimens for the Treatment of INH Mono-resistant TB.....	8-33
Table 8.16: Regimens for the Treatment of RMP Mono-resistant TB.....	8-34
Table 9.1: TST in the Context of a Contact Investigation.....	9-9
Table 10.1: PHA Legislation and NWT Regulation for Public Health Activities for TB Control.....	10-4
Table 11.1: Average Age-Specific Risk For Disease Development After Untreated Primary Infection.....	11-3
Table 11.2: Regimes for Treatment of LTBI in Children.....	11-3
Table 11.3: Doses of Anti-Tuberculosis Drugs for Children.....	11-8
Table 11.4: Drug Regimes for Treating TB in Children.....	11-9
Table 11.5: INH Drug Overdose.....	11-11
Table 12.1: Recommendations of The Canadian Thoracic Society for Groups for Targeted LTBI Screening.....	12-5
Table 14.1: Average Annual Incidence Rates of Active TB per 100,000, and Total Number of Cases by Regional Health and Social Services Authority 1999–2013.....	14-5
Table 17.1: Specimens.....	17-2